ZA925146B - Pharmaceutical agent for treatment of withdrawal symptoms. - Google Patents

Pharmaceutical agent for treatment of withdrawal symptoms.

Info

Publication number
ZA925146B
ZA925146B ZA925146A ZA925146A ZA925146B ZA 925146 B ZA925146 B ZA 925146B ZA 925146 A ZA925146 A ZA 925146A ZA 925146 A ZA925146 A ZA 925146A ZA 925146 B ZA925146 B ZA 925146B
Authority
ZA
South Africa
Prior art keywords
treatment
pharmaceutical agent
withdrawal symptoms
withdrawal
symptoms
Prior art date
Application number
ZA925146A
Other languages
English (en)
Inventor
Karin Gabriele Steppuhn
Karin Bressler
Martin Gieseler
David Norman Stephens
Lechoslaw Turski
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ZA925146B publication Critical patent/ZA925146B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA925146A 1991-07-09 1992-07-09 Pharmaceutical agent for treatment of withdrawal symptoms. ZA925146B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4123106A DE4123106A1 (de) 1991-07-09 1991-07-09 Arzneimittel zur behandlung von entzugssymptomen

Publications (1)

Publication Number Publication Date
ZA925146B true ZA925146B (en) 1993-08-16

Family

ID=6435996

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA925146A ZA925146B (en) 1991-07-09 1992-07-09 Pharmaceutical agent for treatment of withdrawal symptoms.

Country Status (10)

Country Link
US (1) US5385903A (fr)
EP (1) EP0527540A1 (fr)
JP (1) JPH0648959A (fr)
AU (1) AU660471B2 (fr)
CA (1) CA2073396A1 (fr)
DE (1) DE4123106A1 (fr)
HU (1) HUT61466A (fr)
IE (1) IE922232A1 (fr)
IL (1) IL102372A (fr)
ZA (1) ZA925146B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE4222826A1 (de) * 1992-07-09 1994-01-13 Schering Ag Arzneimittel zur Verhinderung der Toleranzentwicklung während der Behandlung mit Benzodiazepin-Rezeptor-Bindenen Wirkstoffen
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2440284A1 (fr) * 2001-03-08 2002-09-19 Emory University Antagonistes du recepteur nmda dependant du ph
PT1551372T (pt) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
US8158156B2 (en) * 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
CA2693032A1 (fr) * 2007-06-29 2009-01-08 Emory University Antagonistes des recepteurs nmda pour la neuroprotection
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US11045462B2 (en) 2016-06-14 2021-06-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods for treating neurological conditions and exposure to nerve agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975430A (en) * 1989-06-16 1990-12-04 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University CNQX and its analogs as therapeutics for degenerative neural diseases
US5095009A (en) * 1990-04-11 1992-03-10 Merrell Dow Pharmaceuticals Inc. NMDA antagonists

Also Published As

Publication number Publication date
HU9202261D0 (en) 1992-10-28
HUT61466A (en) 1993-01-28
DE4123106A1 (de) 1993-01-14
JPH0648959A (ja) 1994-02-22
CA2073396A1 (fr) 1993-01-10
IE922232A1 (en) 1993-01-13
AU1956092A (en) 1993-01-14
AU660471B2 (en) 1995-06-29
IL102372A0 (en) 1993-01-14
IL102372A (en) 1998-06-15
US5385903A (en) 1995-01-31
EP0527540A1 (fr) 1993-02-17

Similar Documents

Publication Publication Date Title
GB9016789D0 (en) Medicament administering devices
ZA823369B (en) Nonapeptide for the treatment of drug withdrawal symptoms
PL297747A1 (en) Prolonged action pharmaceutical dosage forms
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
GR3004150T3 (en) Medicaments for the treatment or prevention of the withdrawal syndrome.
IL103303A0 (en) Medicament
ZA925146B (en) Pharmaceutical agent for treatment of withdrawal symptoms.
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
AU2806692A (en) Medicament for the treatment of anxiety
EP0592903A3 (fr) Utilisation du ancrod pour la préparation de médicaments pour le traitement de la restenosis.
GB9015051D0 (en) Pharmaceutical treatment
ZA92729B (en) Pharmaceutical agent
GB9103278D0 (en) Drug for the treatment of dermatitis
ZA932450B (en) Drugs for the treatment of diabetes
EP0663209A3 (fr) Médicament pour inhiber les effets des protéines amyloidogéniques.
IL111144A0 (en) Pharmaceutical compositions containing amiodarone for the treatment of heart failure
GB9319371D0 (en) Medication administration apparatus
IL99666A0 (en) Pharmaceutical compositions for the treatment of diabetes
EP0653208A3 (fr) Antagonistes de la substance P pour le traitement et la prévention de l'erythème solaire.
IL94402A0 (en) Pharmaceutical compositions containing imidazodiazepines for the treatment of neurological symptoms
CS231590A3 (en) Preparation for hemorrhoids treatment
RO101041B1 (en) Reno-urinary affections treatment medication
GB9324852D0 (en) A medicament for the treatment of metasteses
GB9104123D0 (en) Pharmaceutical agent
GB9104124D0 (en) Pharmaceutical agent